Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | Pembrolizumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab | Phase III | Actionable | In a Phase III trial (KEYNOTE-024), treatment with Keytruda (pembrolizumab) improved progression-free survival (10.3 vs 6.0 months, HR=0.50, p<0.001) and estimated 6-month overall survival rate (80.2% vs 72.4%, HR=0.60, p<0.001) compared to chemotherapy in untreated advanced non-small cell lung cancer patients with CD274 (PD-L1) expression on over 50% of tumor cells, and with no EGFR activating mutations or ALK rearrangement (PMID: 27718847; NCT02142738). | 27718847 |
CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, treatment with immune checkpoint inhibitors including Tecentriq (atezolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) resulted in improved progression-free survival (HR=0.41, p<0.001) and overall survival (HR=0.62, p=0.006) in non-small cell lung cancer patients with high CD274 (PD-L1) expression compared to patients with low CD274 (PD-L1) expression (PMID: 31290993). | 31290993 |
PubMed Id | Reference Title | Details |
---|---|---|
(27718847) | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. | Full reference... |
(31290993) | Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. | Full reference... |